title: Stability of a Vesicular Stomatitis Virus-Vectored Ebola Vaccine.
abstract: The live attenuated vesicular stomatitis virus-vectored Ebola vaccine rVSV-ZEBOV is currently undergoing clinical trials in West Africa. The vaccine is to be stored at -70°C or less. Since maintaining the cold chain is challenging in rural areas, the rVSV-ZEBOV vaccine's short-term and long-term stability at different temperatures was examined. Different dilutions were tested since the optimal vaccine dosage had not yet been determined at the start of this experiment. The results demonstrate that the original vaccine formulation was stable for 1 week at 4°C and for 24 hours at 25°C. The stability of the vaccine was compromised by both high temperatures and dilution.
authors.affiliation: Department of Pharmaceutical Biosciences, School of Pharmacy.
authors.forename: Marianne
authors.initials: M
authors.lastname: Arnemo
authors.affiliation: Norwegian Institute of Public Health, Oslo, Norway.
authors.forename: Sara Sofie
authors.initials: SS
authors.lastname: Viksmoen Watle
authors.affiliation: Norwegian Institute of Public Health, Oslo, Norway.
authors.forename: Kristin Merete
authors.initials: KM
authors.lastname: Schoultz
authors.affiliation: Norwegian Institute of Public Health, Oslo, Norway.
authors.forename: Kirsti
authors.initials: K
authors.lastname: Vainio
authors.affiliation: Norwegian Institute of Public Health, Oslo, Norway.
authors.forename: Gunnstein
authors.initials: G
authors.lastname: Norheim
authors.affiliation: World Health Organization, Geneva, Switzerland.
authors.forename: Vasee
authors.initials: V
authors.lastname: Moorthy
authors.affiliation: World Health Organization, Geneva, Switzerland International AIDS Vaccine Initiative, New York, New York.
authors.forename: Patricia
authors.initials: P
authors.lastname: Fast
authors.affiliation: Department of Health and Society, University of Oslo Norwegian Institute of Public Health, Oslo, Norway Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
authors.forename: John-Arne
authors.initials: JA
authors.lastname: Røttingen
authors.affiliation: Department of Pharmaceutical Biosciences, School of Pharmacy.
authors.forename: Tor
authors.initials: T
authors.lastname: Gjøen
mesh_terms: D000818:Animals; D002522:Chlorocebus aethiops; D046129:Ebola Vaccines / Q000737:chemistry*; D006863:Hydrogen-Ion Concentration; D013696:Temperature; D013997:Time Factors; D064166:Vaccine Potency; D014709:Vero Cells
chemical_list: D046129:Ebola Vaccines
keywords: Ebola; VSV; stability; vaccine; virus